First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

PR Pexa-Vec nivo EN

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2023 Transgene - All rights reserved
Credits